Skip to main content
Log in

Rationally engineered Losmapimod encapsulating polymeric nanoparticles for treatment of human multiple myeloma cells

  • Original Article
  • Published:
Applied Nanoscience Aims and scope Submit manuscript

Abstract

Human multiple myeloma is an incurability of haematological cancer with recurrence rates above 90%. For the successful use of chemotherapy in MM, the critical limiting factor is the severe adverse effects of this drug. The anticancer efficiency of Losmapimod encapsulated in poly(lactic-co-glycolic acid) nanoparticles (LOS@PLGA-NPs) in vitro using multiple myeloma cells has been established. Furthermore, the morphological examination, hydrodynamic size and zeta potential of the nanoparticle were examined by the high-resolution transmission electron microscopy and dynamic light scattering method. The Cell Counting Kit-8 analysis has shown a significant inhibitory impact of LOS@PLGA-NPs on MM cancer cells (U266 and IM9). Furthermore, an investigation of the mechanism showed that apoptosis in cancer cells has performed by anticancer activity. We also demonstrated that such drugs showed promise antimetastatic efficacy and inhibited cancer cell invasiveness. Importantly, LOS@PLGA-NPs have confirmed to indicate that the dramatically better animal safety profile of the LOS is highlighted as prospective candidates for MM cancer treatment using these LOS@PLGA-NPs and deserve further evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Meiyun Su.

Ethics declarations

Conflict of the interest

The authors declare no competing financial interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ye, S., Hou, Z., Su, Y. et al. Rationally engineered Losmapimod encapsulating polymeric nanoparticles for treatment of human multiple myeloma cells. Appl Nanosci 11, 2447–2457 (2021). https://doi.org/10.1007/s13204-021-02010-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13204-021-02010-3

Keywords

Navigation